Eiger BioPharmaceuticals (EIGR) Revenue & Revenue Breakdown
Eiger BioPharmaceuticals Revenue Highlights
Latest Revenue (Y)
$15.77M
Latest Revenue (Q)
$3.80M
Main Segment (Y)
Product
Eiger BioPharmaceuticals Revenue by Period
Eiger BioPharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $15.77M | 16.98% |
| 2022-12-31 | $13.48M | 11.05% |
| 2021-12-31 | $12.14M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2011-06-30 | - | - |
Eiger BioPharmaceuticals generated $15.77M in revenue during NA 2023, up 16.98% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Eiger BioPharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $3.80M | 18.51% |
| 2023-09-30 | $3.21M | -30.89% |
| 2023-06-30 | $4.64M | 12.75% |
| 2023-03-31 | $4.12M | 52.74% |
| 2022-12-31 | $2.70M | -33.00% |
| 2022-09-30 | $4.02M | -1.64% |
| 2022-06-30 | $4.09M | 53.05% |
| 2022-03-31 | $2.67M | -20.45% |
| 2021-12-31 | $3.36M | 10.56% |
| 2021-09-30 | $3.04M | 44.92% |
| 2021-06-30 | $2.10M | -42.48% |
| 2021-03-31 | $3.65M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2012-09-30 | - | - |
Eiger BioPharmaceuticals generated $3.80M in revenue during Q4 2023, up 18.51% compared to the previous quarter, and up 94.51% compared to the same period a year ago.
Eiger BioPharmaceuticals Revenue Breakdown
Eiger BioPharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 |
|---|---|
| Product | $12.73M |
| Other Revenue | $750.00K |
Eiger BioPharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 22: Product (94.44%), and Other Revenue (5.56%).
Quarterly Revenue by Product
| Product/Service | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 |
|---|---|---|---|---|---|
| Other Revenue | $250.00K | - | - | $750.00K | - |
| Product | $4.39M | $4.12M | $2.70M | $4.02M | $3.34M |
Eiger BioPharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 23: Product (94.62%), and Other Revenue (5.38%).
Eiger BioPharmaceuticals Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Mar 23 | Dec 22 | Sep 22 | Jun 22 |
|---|---|---|---|---|
| Product | $4.12M | $2.70M | $4.02M | $3.34M |
| Other Revenue | - | - | - | $750.00K |
Eiger BioPharmaceuticals's latest quarterly revenue breakdown by geography, as of Mar 23: Product (100.00%).
Eiger BioPharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CHRS | Coherus BioSciences | $257.24M | $64.98M |
| SPRO | Spero Therapeutics | $96.73M | $10.20M |
| ETON | Eton Pharmaceuticals | $31.64M | $9.07M |
| HOWL | Werewolf Therapeutics | $19.94M | $742.00K |
| EIGR | Eiger BioPharmaceuticals | $15.77M | $3.80M |
| SPRB | Spruce Biosciences | $10.09M | $1.61M |
| APLT | Applied Therapeutics | $9.99M | $190.00K |
| BOLT | Bolt Biotherapeutics | $7.88M | $1.27M |
| FUSN | Fusion Pharmaceuticals | $2.07M | - |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| UNCY | Unicycive Therapeutics | $675.00K | - |
| FNCH | Finch Therapeutics Group | $107.00K | - |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| GRCL | Gracell Bio | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| CNTB | Connect Biopharma | - | - |
| CING | Cingulate | - | - |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| NLTX | Neurogene | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| NUVB | Nuvation Bio | - | $1.44M |
| ELDN | Eledon Pharmaceuticals | - | - |
EIGR Revenue FAQ
What is Eiger BioPharmaceuticals’s yearly revenue?
Eiger BioPharmaceuticals's yearly revenue for 2023 was $15.77M, representing an increase of 16.98% compared to 2022. The company's yearly revenue for 2022 was $13.48M, representing an increase of 11.05% compared to 2021. EIGR's yearly revenue for 2021 was $12.14M, representing an increase of 100.00% compared to 2020.
What is Eiger BioPharmaceuticals’s quarterly revenue?
Eiger BioPharmaceuticals's quarterly revenue for Q4 2023 was $3.8M, a 18.51% increase from the previous quarter (Q3 2023), and a 41.06% increase year-over-year (Q4 2022). The company's quarterly revenue for Q3 2023 was $3.21M, a -30.89% decrease from the previous quarter (Q2 2023), and a -20.25% decrease year-over-year (Q3 2022). EIGR's quarterly revenue for Q2 2023 was $4.64M, a 12.75% increase from the previous quarter (Q1 2023), and a 13.49% increase year-over-year (Q2 2022).
What is Eiger BioPharmaceuticals’s revenue growth rate?
Eiger BioPharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 29.90%, and for the last 5 years (2019-2023) was 0%.
What are Eiger BioPharmaceuticals’s revenue streams?
Eiger BioPharmaceuticals's revenue streams in c 22 are Product, and Other Revenue. Product generated $12.73M in revenue, accounting 94.44% of the company's total revenue Other Revenue generated $750K in revenue, accounting 5.56% of the company's total revenue
What is Eiger BioPharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of Eiger BioPharmaceuticals was Product. This segment made a revenue of $12.73M, representing 94.44% of the company's total revenue.